Yuval Cohen founded Celsus Therapeutics Plc. He is Chief Executive Officer & Director at Corbus Pharmaceuticals Holdings, Inc. and Chief Executive Officer & Director at Corbus Pharmaceuticals, Inc. (a subsidiary of Corbus Pharmaceuticals Holdings, Inc.).
In the past Yuval Cohen was Director & Senior Vice President at Celsus Therapeutics Plc.
Dr. Cohen received an undergraduate degree from the University of Cape Town and a doctorate from the University of Paris V.
|11/11/2020||4,240||Acquisition at $1.21 per share.||5,130|
|03/17/2020||4,300||Acquisition at $3.49 per share.||15,007|
|11/12/2019||1,430||Acquisition at $4.26 per share.||6,091|
|08/12/2019||1,175||Acquisition at $6.06 per share.||7,120|
|05/13/2019||995||Acquisition at $6.99 per share.||6,955|
|03/14/2019||1,530||Acquisition at $6.49 per share.||9,929|
|05/15/2018||1,725||Acquisition at $5.85 per share.||10,091|
|03/14/2018||1,160||Acquisition at $6.88 per share.||7,980|
|11/10/2017||1,000||Acquisition at $7.17 per share.||7,170|
|08/11/2017||1,695||Acquisition at $6 per share.||10,170|
|05/11/2017||3,250||Acquisition at $6.01 per share.||19,532|
|03/16/2017||20,000||Derivative/Non-derivative trans. at $1 per share.||20,000|
|11/22/2016||1,340||Acquisition at $7.64 per share.||10,237|
|08/17/2016||20,000||Derivative/Non-derivative trans. at $1 per share.||20,000|
|06/06/2016||1,500||Acquisition at $3.34 per share.||5,010|
|05/18/2016||2,125||Acquisition at $2.4 per share.||5,100|